Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Oral Linezolid Induced Early Onset Hepatic Encephalopathy- A Case Report of 65-year Old Diabetic Female

Author(s): Mitul Upadhyay*, Bhargav Purohit and Piyush Pargi

Volume 19, Issue 1, 2024

Published on: 04 May, 2023

Page: [151 - 153] Pages: 3

DOI: 10.2174/1574886318666230417113910

Price: $65

Abstract

Introduction: Linezolid is increasingly utilized to treat gram-positive bacteria that are resistant to other antibiotics like vancomycin-resistant Staphylococcus aureus, methicillinresistant Staphylococcus aureus as well as drug-resistant tuberculosis. It acts by inhibiting protein synthesis in bacteria. Although it is a relatively safe medicine, many reports of hepatotoxicity and neurotoxicity linked to long-term usage have been received but patients with pre-existing risk factors, such as diabetes and alcoholism, may have toxicity even after short-term use of linezolid.

Case Presentation: Here we are presenting a case of a 65-year-old female with diabetes who developed hepatic encephalopathy after one week of treatment with linezolid prescribed for nonhealing diabetic ulcer after a culture sensitivity test. After the use of linezolid 600 mg BD for 8 days patient developed altered sensorium and breathlessness and had high bilirubin, SGOT, and SGPT. She was diagnosed with hepatic encephalopathy. Linezolid was withdrawn and after 10 days all laboratory parameters for liver function test were improved.

Conclusion: Care should be taken when prescribing linezolid in such patients with pre-existing risk factors as they are prone to develop hepatotoxic and neurotoxic adverse effects even after short-term use of linezolid.

« Previous Next »
Graphical Abstract

[1]
Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill New York: 1996.
[2]
Sharma HL, Sharma KK. Principles of pharmacology. Paras medical publisher 2007.
[3]
Fletcher J, Aykroyd LE, Feucht EC, Curtis JM. Early onset probable linezolid-induced encephalopathy. J Neurol 2010; 257(3): 433-5.
[http://dx.doi.org/10.1007/s00415-009-5340-y] [PMID: 19888623]
[4]
Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 2005; 37(2): 153-4.
[http://dx.doi.org/10.1080/00365540410026022] [PMID: 15764207]
[5]
Nagel S, Köhrmann M, Huttner HB, Storch-Hagenlocher B, Schwab S. Linezolid-induced posterior reversible leukoencephalopathy syndrome. Arch Neurol 2007; 64(5): 746-8.
[http://dx.doi.org/10.1001/archneur.64.5.746] [PMID: 17502475]
[6]
De Vriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42(8): 1111-7.
[http://dx.doi.org/10.1086/501356] [PMID: 16575728]
[7]
Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Molecular cell 1981; 26(3): 393-402.
[8]
Naranjo C, Busto U, Sellers E, et al. Probability scale. Clin Pharmacol Ther 1981; 30: 239-45.
[9]
WHOcausality_assessment.pdf. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficac y/WHOcausality_assessment.pdf
[10]
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538.
[PMID: 10118597]
[11]
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm 1992; 49(9): 2229-32.
[http://dx.doi.org/10.1093/ajhp/49.9.2229] [PMID: 1524068]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy